Department of Ophthalmology, University of Washington, Seattle.
Department of Cornea and Refractive Surgery, Aravind Eye Care System, Madurai, India.
JAMA Ophthalmol. 2020 Feb 1;138(2):113-118. doi: 10.1001/jamaophthalmol.2019.4852.
Corneal opacity is a leading cause of visual impairment worldwide; however, the specific features of corneal scars, which decrease visual acuity, have not been well characterized.
To investigate which features of a postfungal keratitis corneal scar contribute to decreased visual acuity after an episode of infectious keratitis and evaluate whether any corneal features may be used as outcomes for clinical trials.
DESIGN, SETTING, AND PARTICIPANTS: In this ancillary, prospective cross-sectional study, a subset of study participants treated for fungal keratitis (n = 71) as part of the Mycotic Ulcer Treatment Trial I (MUTT I) underwent best spectacle-corrected visual acuity (BSCVA) and best contact lens-corrected visual acuity examination, Scheimpflug imaging, and anterior segment optical coherence tomography at a referral hospital in India approximately 2 years after enrollment. Data were collected from December 3, 2012, to December 19, 2012, and analyses were performed from December 2, 2013, to October 2, 2019.
Linear regression models were used to evaluate the importance of various corneal features for BSCVA and to assess whether these features could be used to differentiate the 2 treatment arms of the MUTT I trial.
Seventy-one patients (42 men [59.1%]; median age, 48 [range, 39-60] years) were examined at a median (IQR) time of 1.8 (1.4-2.2) years after enrollment. The mean (SD) logMAR BSCVA was 0.17 (0.19) (Snellen equivalent, 20/32). In multivariable linear regression models, BSCVA was most associated with irregular astigmatism (1.0 line of worse BSCVA per 1-line difference between BSCVA and contact lens visual acuity; 95% CI, 0.6-1.4) and corneal scar density (1.5 lines of worse vision per 10-unit increase in the mean central corneal density; 95% CI, 0.8-2.3). The thinnest point of the cornea was the metric that best discriminated between the natamycin- and voriconazole-treated ulcers in MUTT I, with 29.3 μm (95% CI, 7.1-51.6 μm) less thinning in natamycin-treated eyes.
Both irregular astigmatism and corneal scar density may be important risk factors for BSCVA in a population with relatively mild, healed fungal corneal ulcers. The thinnest point of the corneal scar may be a cornea-specific outcome that could be used to evaluate treatments for corneal ulcers.
角膜混浊是全球视力损害的主要原因;然而,降低视力的角膜瘢痕的具体特征尚未得到很好的描述。
研究真菌性角膜炎后角膜瘢痕的哪些特征导致传染性角膜炎发作后的视力下降,并评估任何角膜特征是否可作为临床试验的结果。
设计、地点和参与者:在这项辅助的、前瞻性的横断面研究中,Mycotic Ulcer Treatment Trial I(MUTT I)中接受抗真菌治疗的研究参与者(n=71)的一个亚组在印度的一家转诊医院接受了最佳矫正视力(BSCVA)和最佳隐形眼镜矫正视力检查、Scheimpflug 成像和眼前节光学相干断层扫描,大约在入组后 2 年进行。数据于 2012 年 12 月 3 日至 2012 年 12 月 19 日收集,分析于 2013 年 12 月 2 日至 2019 年 10 月 2 日进行。
线性回归模型用于评估各种角膜特征对 BSCVA 的重要性,并评估这些特征是否可用于区分 MUTT I 试验的 2 个治疗臂。
71 名患者(42 名男性[59.1%];中位年龄 48 [范围,39-60]岁)在入组后中位数(IQR)1.8(1.4-2.2)年接受检查。平均(SD)logMAR BSCVA 为 0.17(0.19)(Snellen 等价物,20/32)。在多变量线性回归模型中,BSCVA 与不规则散光最相关(BSCVA 每相差 1 行,BCVA 与隐形眼镜视力相差 1 行;95%CI,0.6-1.4)和角膜瘢痕密度(中央角膜密度每增加 10 个单位,视力下降 1.5 行;95%CI,0.8-2.3)。角膜最薄点是区分 MUTT I 中那他霉素和伏立康唑治疗溃疡的最佳指标,那他霉素治疗眼的角膜最薄点减少了 29.3 μm(95%CI,7.1-51.6 μm)。
在患有相对较轻、已愈合的真菌性角膜溃疡的人群中,不规则散光和角膜瘢痕密度可能都是 BSCVA 的重要危险因素。角膜瘢痕的最薄点可能是一种特定于角膜的结果,可用于评估角膜溃疡的治疗效果。